Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | FT538 |
Trade Name | |
Synonyms | FT-538|FT 538 |
Drug Descriptions |
FT538 consists of a preparation of natural killer cells derived from induced pluripotent stem cells engineered to lack CD38 and to express an IL-15 receptor alpha fusion protein and a non-cleavable form of CD16, which potentially induces enhanced antibody-dependent cellular cytotoxicity against tumor cells (Blood (2019) 134 (Supplement_1): 133). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C176623 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + FT538 | Atezolizumab FT538 | 0 | 1 |
Avelumab + FT538 | Avelumab FT538 | 0 | 1 |
Cetuximab + FT538 | Cetuximab FT538 | 0 | 1 |
Daratumumab + FT538 | Daratumumab FT538 | 0 | 1 |
Daratumumab and hyaluronidase-fihj + FT538 | Daratumumab and hyaluronidase-fihj FT538 | 0 | 1 |
Elotuzumab + FT538 | Elotuzumab FT538 | 0 | 1 |
FT538 | FT538 | 0 | 2 |
FT538 + MGA271 | FT538 MGA271 | 0 | 1 |
FT538 + Nivolumab | FT538 Nivolumab | 0 | 1 |
FT538 + Pembrolizumab | FT538 Pembrolizumab | 0 | 1 |
FT538 + Trastuzumab | FT538 Trastuzumab | 0 | 1 |